Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus FERNISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus FERNISONE.
CORTIFOAM vs FERNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
FERNISONE is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
40 mg orally once daily
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 18-24 hours in healthy adults. In elderly (age >65), half-life increases to 30-36 hours due to reduced renal function. In moderate renal impairment (CrCl 30-60 mL/min), half-life extends to 40-48 hours. Clinical context: requires dose adjustment in renal impairment; steady-state reached in 3-5 days.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal excretion of unchanged drug and metabolites: ~60% (30% unchanged, 30% metabolites). Biliary/fecal elimination: ~35% (primarily as metabolites). Minor metabolic clearance via CYP3A4. About 5% eliminated in sweat and saliva.
Category C
Category C
Corticosteroid
Corticosteroid